Overview

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Oncology Research Center, LLC
Treatments:
Dacarbazine
Gemcitabine
Trabectedin